120 related articles for article (PubMed ID: 9276743)
1. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.
Brasoveanu LI; Fonsatti E; Visintin A; Pavlovic M; Cattarossi I; Colizzi F; Gasparollo A; Coral S; Horejsi V; Altomonte M; Maio M
J Clin Invest; 1997 Sep; 100(5):1248-55. PubMed ID: 9276743
[TBL] [Abstract][Full Text] [Related]
2. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement.
Coral S; Fonsatti E; Sigalotti L; De Nardo C; Visintin A; Nardi G; Colizzi F; Colombo MP; Romano G; Altomonte M; Maio M
J Cell Physiol; 2000 Dec; 185(3):317-23. PubMed ID: 11056001
[TBL] [Abstract][Full Text] [Related]
4. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.
De Nardo C; Fonsatti E; Sigalotti L; CalabrĂ² L; Colizzi F; Cortini E; Coral S; Altomonte M; Maio M
J Cell Physiol; 2002 Feb; 190(2):200-6. PubMed ID: 11807824
[TBL] [Abstract][Full Text] [Related]
5. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells.
Junnikkala S; Hakulinen J; Meri S
Eur J Immunol; 1994 Mar; 24(3):611-5. PubMed ID: 7510237
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
Hakulinen J; Meri S
Lab Invest; 1994 Dec; 71(6):820-7. PubMed ID: 7528832
[TBL] [Abstract][Full Text] [Related]
7. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity.
Brasoveanu LI; Altomonte M; Gloghini A; Fonsatti E; Coral S; Gasparollo A; Montagner R; Cattarossi I; Simonelli C; Cattelan A
Int J Cancer; 1995 May; 61(4):548-56. PubMed ID: 7538980
[TBL] [Abstract][Full Text] [Related]
8. Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules.
Hakulinen J; Meri S
Immunology; 1995 Jul; 85(3):495-501. PubMed ID: 7558140
[TBL] [Abstract][Full Text] [Related]
9. CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis.
Brooimans RA; Van der Ark AA; Tomita M; Van Es LA; Daha MR
Eur J Immunol; 1992 Mar; 22(3):791-7. PubMed ID: 1372260
[TBL] [Abstract][Full Text] [Related]
10. Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement.
Jokiranta TS; Meri S
J Immunol; 1993 Aug; 151(4):2124-31. PubMed ID: 7688394
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies.
Fonsatti E; Altomonte M; Coral S; De Nardo C; Lamaj E; Sigalotti L; Natali PG; Maio M
Clin Ter; 2000; 151(3):187-93. PubMed ID: 10958054
[TBL] [Abstract][Full Text] [Related]
12. Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement.
Walsh LA; Tone M; Waldmann H
Eur J Immunol; 1991 Mar; 21(3):847-50. PubMed ID: 1707009
[TBL] [Abstract][Full Text] [Related]
13. CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity.
Marcenaro E; Augugliaro R; Falco M; Castriconi R; Parolini S; Sivori S; Romeo E; Millo R; Moretta L; Bottino C; Moretta A
Eur J Immunol; 2003 Dec; 33(12):3367-76. PubMed ID: 14635045
[TBL] [Abstract][Full Text] [Related]
14. Primary human hepatocytes are protected against complement by multiple regulators.
Halme J; Sachse M; Vogel H; Giese T; Klar E; Kirschfink M
Mol Immunol; 2009 Jul; 46(11-12):2284-9. PubMed ID: 19446335
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal mesothelial cells produce complement factors and express CD59 that inhibits C5b-9-mediated cell lysis.
Barbano G; Cappa F; Prigione I; Tedesco F; Pausa M; Gugliemino R; Pistoia V; Gusmano R; Perfumo F
Adv Perit Dial; 1999; 15():253-7. PubMed ID: 10682113
[TBL] [Abstract][Full Text] [Related]
16. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
Chen S; Caragine T; Cheung NK; Tomlinson S
Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
[TBL] [Abstract][Full Text] [Related]
17. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
19. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation.
Capey S; van den Berg CW
Xenotransplantation; 2005 May; 12(3):217-26. PubMed ID: 15807772
[TBL] [Abstract][Full Text] [Related]
20. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).
Maio M; Brasoveanu LI; Coral S; Sigalotti L; Lamaj E; Gasparollo A; Visintin A; Altomonte M; Fonsatti E
Int J Oncol; 1998 Aug; 13(2):305-18. PubMed ID: 9664126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]